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Introduction {#sec1}
============

Homeostasis of most tissues and organs results from constant regeneration and remodeling due to the function of adult stem cells, which are characterized by unlimited division capacity and the ability to give rise to all progenies of the differentiated cells required to form a functional tissue. Unsurprisingly, alterations of stem cell biology are associated with many human physiopathological disorders including cancer. Indeed, tumor heterogeneity stems, in part, from the presence of cancer stem cells (CSCs), a cellular population endowed with self-renewal properties able to initiate tumors ([@bib26]). In breast cancers, markers such as CD44 and aldehyde dehydrogenase (ALDH) allow the identification and purification of CSCs, the abundance of which correlates with tumor progression and metastatic spreading ([@bib8], [@bib20]). Although the current understanding of the mechanisms of CSC emergence remains sparse, there is a consensus on the involvement of cell polarity alterations, notably due to the role of asymmetrical cell division in stem cell pool maintenance ([@bib26]). In addition, stem cells and CSC self-renewal have been linked to alterations of NOTCH, Hedgehog, Hippo ([@bib27]), and WNT ([@bib18]) signaling, some of which have been causally linked to dysfunctional cell polarity. This is notably the case for Scrib, a LAP (LRR and PDZ) family member, which regulates planar cell polarity through Hippo and β-catenin independent WNT signaling ([@bib24]). SCRIB function has been extensively studied in mammary gland development ([@bib9]) and cancer progression using *Scrib*-deficient ([@bib28]) or overexpressing ([@bib6]) mouse models. In breast cells, we and others have shown that loss of SCRIB expression impairs directional cell migration ([@bib4], [@bib17]) and apico-basal cell polarity ([@bib15]) through the initiation of an EMT-like (epithelial-mesenchymal transition) process concomitantly with the acquisition of CSC properties ([@bib2]).

We have previously cloned and characterized a mammalian *SCRIB* paralog, *LANO/LRRC1*, hereafter referred to as Lano, which encodes a protein sharing 60% amino acid identity with SCRIB, despite the lack of a PDZ domain ([@bib22], [@bib23]). Given the importance of *SCRIB* in mammary gland development ([@bib9]) and in tumorigenesis ([@bib2], [@bib6], [@bib28]), we decided to evaluate the contribution of *LANO* in these processes.

Results {#sec2}
=======

*LANO* and *SCRIB* Exhibit Different Expression Patterns in Mammary Epithelial Cell Hierarchy {#sec2.1}
---------------------------------------------------------------------------------------------

To examine the potential role of *LANO* in normal human mammary gland, we first compared its expression pattern with that of *SCRIB* by immunofluorescence. SCRIB is mostly expressed in epithelial cells of the luminal layer ([@bib9]) of the mammary gland and absent in the myoepithelial layer, as shown by smooth muscle antigen staining ([Figure 1](#fig1){ref-type="fig"}A). As reported, both proteins are mostly located at the basolateral membrane ([@bib15], [@bib22]) where they co-localize as illustrated by their intensity fluorescent profiles ([Figure 1](#fig1){ref-type="fig"}B) with a Pearson\'s correlation coefficient of 0.69 (±0.03, n = 3). Furthermore, the transcription profiles of *LANO* and *SCRIB* were extracted from a public RNA microarray dataset from the human mammary epithelial cell hierarchy ([@bib14]). *SCRIB* mRNA levels are the same in all subsets of the human mammary epithelial cell hierarchy ([Figure 1](#fig1){ref-type="fig"}C). Interestingly, *LANO* transcript levels are unevenly distributed with low expression among the mammary stem cell (MaSC) subsets and increased levels along the luminal differentiation pathway, from luminal progenitors to mature luminal cells 1--2 ([Figure 1](#fig1){ref-type="fig"}D). Similar results ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B) were obtained from mouse counterpart datasets ([@bib11]). To determine the consequences of loss of *Lano* function on mammary gland development, we generated a *Lano* knockout mouse strain ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). Mice devoid of *Lano* are viable and fertile with a normal Mendelian distribution. Loss of Lano expression was confirmed by immunoblot on mammary gland lysates ([Figure 1](#fig1){ref-type="fig"}E). The kinetics of epithelial mammary ductal tree development was studied by Mayer\'s hemalum staining of 6-week-old mouse mammary glands. In *Lano* mutant mice, the growth of mammary ductal tree embedded in fat pad is significantly delayed ([Figure 1](#fig1){ref-type="fig"}F), which is correlated with a reduction in the number of terminal end buds (TEBs). The growth of mammary ductal tree recovers to normal levels at 12 weeks, when mature mouse mammary glands of all genotypes appear normal (data not shown). While the involvement of *Scrib* in stem cell fate is established in various cellular contexts ([@bib19]), in the mammary gland, stem cell fate seems not to be related to *Scrib* expression, nor is ductal tree development ([@bib2], [@bib9]). Altogether, these data suggest that Lano contributes to MaSC fate and function in normal breast tissue as well as in early mouse mammary gland development.Figure 1*SCRIB* and *LANO* Expression in Human and Murine Mammary Gland(A) Scrib and Lano immunofluorescence staining in normal human mammary gland sections with the indicated antibodies. Scale bar, 5 μm.(B) Localization profiles of Lano and Scrib (right panel) along the red line are depicted in the left panel.(C--F) (C and D) Expression levels of *SCRIB* and *LANO/LRRC1* in human normal breast reported as a box plot. MaSC, mammary stem cell subsets; LP, luminal progenitors; mL, mature luminal cells. Statistical analysis was performed using one-way ANOVA with Tukey's post test. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. Pubescent 6-week-old mouse inguinal mammary glands of wild-type (wt) (n = 2) or *Lano* knockout mice (n = 4) were analyzed (E) by immunoblot for Scrib and Lano protein expression, with α-tubulin as loading control, and (F) by Mayer\'s hemalum whole-mount staining to visualize the epithelial tree. Lymph node (LN) is used as a marker (left panel). Quantifications of percentage of relative duct area (middle panel) and TEBs number (right panel) are shown.(G) Bar plots represent significance of univariate linear regression analysis of *LANO*/*LRRC1* (blue) and *SCRIB* (red) with stem cell and stroma signatures. Each bar score was defined as the log-transformed p value (−log~10~) and weighted by direction of association for analysis. Thus, at 5% risk, a score above 1.3 or under −1.3 was considered significant. ALDges, ALDH gene expression signature; MS-like, mammosphere-like; PLAU, plasminogen activator urokinase.

Low *LANO* Expression Is Associated with a CSC Signature in Human Breast Tumors {#sec2.2}
-------------------------------------------------------------------------------

The differential expression of *LANO* in normal mammary gland cell populations led us to investigate a possible correlation between its mRNA levels and gene signatures in breast cancers. We carried out a univariate transcriptomic analysis using 9,057 patient tumor samples of all breast cancer subtypes gathered from 36 public datasets ([Table S1](#mmc1){ref-type="supplementary-material"}). The results from these analyses ([Figure 1](#fig1){ref-type="fig"}G and [Table S2](#mmc1){ref-type="supplementary-material"}) show that low *LANO* mRNA expression correlates with MaSC ([@bib11]) and CSC signatures ([@bib1], [@bib3]). In addition, *LANO* was also associated with a core EMT signature ([@bib25]) which characterizes a process essential for the acquisition of stemness properties in normal and tumor cells ([@bib13]). Similar analyses performed for *SCRIB* also show that low *SCRIB* transcript levels are associated with a CSC signature, as previously described ([@bib2]), but to lesser extent than for *LANO*. Indeed, in contrast to *LANO*, the association of *SCRIB* with a CSC signature is limited to a subset of CSC markers, and no association was found with the Charafe-Jauffret and Prat signatures ([@bib1], [@bib21]). Conversely, the association of *SCRIB* with EMT signatures appears significantly stronger than that of *LANO* ([Figure 1](#fig1){ref-type="fig"}G and [Table S2](#mmc1){ref-type="supplementary-material"}).

Thus, these results suggest that low *LANO* mRNA levels correlate with MaSC signatures in normal or pathological situations across all breast cancer subtypes.

*LANO* Knockdown Leads to the Expansion of Breast CSCs {#sec2.3}
------------------------------------------------------

We then asked whether *LANO* expression, in addition to being a marker of cell differentiation, actively contributes to repress stemness properties of breast cancer cells. For this purpose, we used a short hairpin RNA (shRNA) approach to analyze the consequences of stable Lano depletion in two breast cancer cell lines, SUM149 and SUM159, which both contain a cell population subset (ALDH^br^) with CSC-like features ([@bib1]). For each cell line, Lano-depleted cell populations were obtained using two different targeting sequences, shLano1 and shLano3. Knockdown efficiency was tested by immunoblot using parental cells or transfected by shRNA targeting the green fluorescent protein (shGFP) as controls ([Figure 2](#fig2){ref-type="fig"}A). In both cell lines, Lano expression was decreased to lower than 80% of wild-type levels while Scrib expression was unaffected, which demonstrates the specificity of the Lano-shRNAs. The use of a monoclonal antibody (811) binding a shared epitope of Lano and Scrib ([Figure S2](#mmc1){ref-type="supplementary-material"}A) allowed us to compare their relative abundance and to exclude any compensation of *LANO* expression loss by *SCRIB*. The percentage of CSCs present in each SUM149 and SUM159 cell population was determined by measuring their ALDH enzymatic activity ([@bib8]). SUM149 or SUM159 cell populations depleted for Lano contain two to five times more cells harboring ALDH activity than the corresponding shGFP control cells ([Figures 2](#fig2){ref-type="fig"}B and 2C). To functionally confirm the higher ALDH activity as the breast CSC (bCSC) population increases in Lano-depleted conditions we performed mammosphere assays, which indeed showed a significant fold increase of sphere-forming efficiency (SFE) in Lano-depleted cells compared with the shGFP control conditions in both cell lines ([Figures 2](#fig2){ref-type="fig"}D and 2E). To exclude a potential off-target effect, we carried out rescue experiments of mammosphere assays by re-expressing HA-tagged Lano, which confirmed the innocuity of ectopic expression of HA-Lano on Scrib expression levels ([Figure 2](#fig2){ref-type="fig"}F). As expected, the variations of SFE between Lano-depleted and control (shGFP) cells were abolished or reverted by ectopic re-expression of HA-Lano ([Figures 2](#fig2){ref-type="fig"}G and 2H). Besides, to evaluate the impact on the tumorigenicity of cell populations depleted for Lano (or not), *in vivo* approaches were conducted through orthotopic xenografts of SUM149 cell populations in the fat pads of NOD/SCID/γc null immunodeficient mice (NSG) ([@bib8]). Tumor growth kinetics showed that fat pads engrafted with 1 × 10^6^ SUM149 cells devoid of Lano gave rise to tumors significantly faster than control conditions ([Figure 2](#fig2){ref-type="fig"}I). Through limiting dilution assays and analysis, the number of bCSCs was found to be lower in the control tumor cell population SUM149 shGFP, 1:4,326 (confidence interval \[CI\] 0.78--6.83) than in the Lano-depleted cell population SUM149 shLano1, 1:615 (CI 5.42--48.63, p = 2.35 × 10^−2^) and shLano3, 1:143 (CI 18.21--266.6, p = 2.0 × 10^−4^) ([Figures 2](#fig2){ref-type="fig"}J and 2K). These *in vivo* observations confirm our *in vitro* results and support a role of Lano in bCSC fate decision.Figure 2*LANO* Downregulation Increases Stemness Properties of bCSC Models *In Vitro* and *In Vivo*(A) Immunoblot analysis of shGFP, shLano1, and shLano3 cell populations probed with the antibodies indicated. Quantification of Lano expression is indicated below.(B and C) Percentage of ALDH^br^ cells for (B) SUM149 and (C) SUM159 (n = 3 for both).(D and E) Sphere-forming efficiency (SFE) compared with the control of cell populations expressed as fold, for SUM149 (D; n = 3) and SUM159 (E; n = 4).(F--H) SFE of SUM149 (G) and SUM159 (H) cells defined in (F) expressed as fold (n = 3).(I) Kinetics of tumor growth of SUM149 cells of each population orthotopically xenografted in NSG mice.(J and K) Table (J) showing the number of outgrowths generated as a function of the amount of injected cells (K). bCSC frequencies were calculated using an extreme limiting dilution analysis algorithm (shLano1 versus shGFP, p = 0.0235; shLano3 versus shGFP, p = 0.0002).Results are expressed as mean ± SD, n for independent experiment, statistical significance using Kruskal-Wallis ANOVA with Dunnett\'s post test. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

*LANO* Depletion Contributes to Metastatic Spreading {#sec2.4}
----------------------------------------------------

Because the bCSC population is described to be the seed of distant metastasis, we assessed whether *LANO* knockdown has an impact on cell motility and metastatic dissemination. First, we monitored the ability of shLano cells to disseminate to the lung and observed ([Figure 3](#fig3){ref-type="fig"}A) that shLano cells led to higher numbers of lung metastasis than shGFP-expressing cells. Besides, the higher metastatic capacity of Lano-deficient cells was correlated with their significantly higher velocity compared with control conditions, as measured by *in vitro* wound-healing assays on SUM149 and SUM159 ([Figures 3](#fig3){ref-type="fig"}B--3D), and confirmed by rescue experiments ([Figures 3](#fig3){ref-type="fig"}E and 3F). Altogether, these results demonstrate that *LANO* downregulation expands the bCSC compartment and contributes, at least in part, to metastatic dissemination.Figure 3*LANO* Knockdown Contributes to Metastatic Spreading(A) Representative microphotographs of metastatic lungs of xenografted mice described in [Figure 2](#fig2){ref-type="fig"}I, and chemoluminescence measurements by PhotonIMAGER in rainbow scale and related graph plotted.(B) Representative images of wound-healing experiments for the shGFP, shLano1, and shLano3 SUM149 and SUM159 cell populations.(C and D) Speed of wound closure represented in μm^2^/min for SUM149 (C) and SUM159 (D) (n = 4).(E and F) Same as in (C) and (D) for cells expressing, or not, HA-tagged wild-type human Lano (n = 3).Results are expressed as mean ± SD, n for independent experiment, statistical significance using Kruskal-Wallis ANOVA with Dunnett\'s post test. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

*LANO* Regulates bCSC Fate through the Wnt/β-Catenin Pathway {#sec2.5}
------------------------------------------------------------

To define the molecular mechanism by which *LANO* affects bCSC fate determination, we first addressed whether *LANO* has any effect on the stabilization of TAZ, a terminal effector of the Hippo pathway, as is the case for SCRIB ([@bib2]). Since TAZ contributes to Hippo and WNT/β-catenin ([@bib27]) signaling, we measured the activation of both of them using firefly luciferase gene reporters under the control of TEAD or TCF/LEF response elements to monitor Hippo or WNT/β-catenin transcriptional activities, respectively. Although Lano downregulation did not significantly affect TEAD transcriptional levels, it increased TCF/LEF activity 2-fold as compared with shGFP control conditions ([Figure 4](#fig4){ref-type="fig"}A). These results were confirmed by immunoblots in which TAZ and its paralog YAP expression levels appeared unaffected by loss of Lano expression, whereas active β-catenin levels were significantly increased ([Figures 4](#fig4){ref-type="fig"}B and 4C). Strikingly, whereas active β-catenin is normally resistant to degradation ([@bib18]), its total expression levels did not seem to be affected. We hypothesized that this might be due to the restriction of WNT/β-catenin upregulation to a subset of bCSCs affected by Lano knockdown. To test this possibility, we stained for active β-catenin sorted bCSC (ALDH^br^) and non-bCSC (ALDH^neg^) cell populations depleted (or not) for Lano. It appeared that bCSCs from the Lano-depleted condition have significantly higher levels of active β-catenin than bCSCs from the shGFP control condition, while no variations were found in non-bCSCs ([Figures 4](#fig4){ref-type="fig"}D and 4E). Finally, rescue experiments were carried out in which ectopic expression of HA-tagged Lano restored active β-catenin levels ([Figures 4](#fig4){ref-type="fig"}F and 4G) as well as TCF/LEF transcriptional activity ([Figure 4](#fig4){ref-type="fig"}H) in shLano3 cell population to levels similar to that found in shGFP-transfected cells.Figure 4*LANO* Represses Wnt Ligand Secretion(A) Fold induction of TEAD and TCF/LEF transcriptional activity by luciferase reporter assays (n = 6).(B) Immunoblot analysis for the indicated antibodies.(C) Fold induction of active β-catenin (act-β-cat) quantified by immunoblot (n = 3) related to shGFP.(D) Representative microphotographs of SUM149 cell populations sorted for either ALDH^br^ or ALDH^neg^ status cytospinned and immunolabeled for active β-catenin antibody (green) and nucleus (blue).(E) Quantification as fluorescent mean intensity of active β-catenin normalized by cell area (n = 2).(F--H) (F) and (G) as in (B) and (C) for Lano rescued cell populations, and (H) their use in TCF/LEF transcriptional activity assay (n = 5).(I and J) shGFP SUM149 cells were co-cultured with indicated cell population growing in Transwell insert prior immunoblot for active β-catenin analysis (I) and quantified as fold related to shGFP (J) (n = 3).(K) Overnight cultured shGFP SUM149 cells were treated with the indicated conditioned medium (CM) prior to mammosphere formation assay (n = 3).(L) TCF/LEF transcriptional assay, same as in (A) for cells treated for 15 hr with DMSO (vehicle) or 20 μM IWP2 prior analysis (n = 4).(M) Amount of WNT3a in culture medium measured by ELISA (n = 5).Results are expressed as mean ± SD, n for independent experiment, statistical significance using Kruskal-Wallis ANOVA with Dunnett\'s post test. ^∗^p \< 0.05, ^∗∗^p \< 0.01.

Overall these data suggest that *LANO* downregulation affects bCSC fate through a specific increase of WNT/β-catenin activity.

Lano Represses WNT Ligand Secretion {#sec2.6}
-----------------------------------

Alterations of WNT/β-catenin activity can be due to either a cell-autonomous process whereby cell signaling defects affect β-catenin degradation or nuclear shuttling ([@bib18]), or non-cell-autonomous processes whereby defects are related to an imbalance between WNT ligand and its inhibitors, such as Dickkopf, in the cell environment ([@bib16], [@bib18]). To define the underlying signaling between Lano and WNT/β-catenin, we performed compartmentalized cultures of SUM149 shGFP cells with cells depleted of Lano separated by a porous membrane with 0.4 μm pore size. After 48 hr, the shGFP cell population was harvested and subjected to immunoblot to monitor active and total β-catenin levels ([Figures 4](#fig4){ref-type="fig"}I and 4J). Similarly, mammosphere assays of shGFP cells were performed using conditioned media originating from Lano-depleted cells ([Figure 4](#fig4){ref-type="fig"}K). These experiments revealed that SUM149 shGFP cells exhibit higher active β-catenin or mammosphere numbers when cultured with Lano-depleted cells or with their culture medium. These results suggest that Lano-deficient cells secrete soluble factors able to activate the WNT/β-catenin signaling pathway. To assess whether this secreted factor might be a WNT ligand, we performed additional TCF/LEF luciferase assays of cells treated with IWP2, an inhibitor of Porcupine, an enzyme required for the final steps of WNT ligand maturation and its subsequent secretion. As shown in [Figure 4](#fig4){ref-type="fig"}L, IWP2 treatment reduced the WNT/β-catenin activity of Lano-depleted cells to levels similar to those of control shGFP cell populations, showing the likely contribution of a WNT ligand. Since SUM149 and SUM159 cells have been described to secrete WNT3a ligand ([@bib5]), we quantified its abundance in the cell culture media by ELISA, and found it to be higher in both cell lines in Lano-depleted conditions ([Figure 4](#fig4){ref-type="fig"}M) than in the media of corresponding control cells. In addition, the impact of *LANO* depletion on WNT3a transcript levels was analyzed in both cell lines and did not reveal significant variation ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Finally, WNT3a transcription profiles extracted from public datasets from the human ([Figure S1](#mmc1){ref-type="supplementary-material"}D) or mouse ([Figure S1](#mmc1){ref-type="supplementary-material"}C) mammary epithelial hierarchy were also analyzed and appeared stable in all subsets, and therefore unrelated to *LANO* transcript levels. Altogether, these results strongly suggest that the WNT/β-catenin activity of CSC observed in cells deficient for Lano is due, at least in part, to an increase in WNT3a secretion acting in a paracrine or autocrine manner.

Discussion {#sec3}
==========

In this study, we demonstrate that *LANO* expression regulates the stem cell fate of normal and tumor-derived mammary glands. Although a similar effect has been described for its paralog *SCRIB* ([@bib2], [@bib9]), the mechanisms underlying this common feature are quite different. Downregulation of *SCRIB* or its delocalization triggers cell-autonomous signaling disorders mainly mediated through the Hippo pathway ([@bib2]), whereas for *LANO* a cell-non-autonomous mechanism is involved through the secretion of WNT3a acting in a paracrine manner. In addition to these distinct molecular mechanisms, *SCRIB* and *LANO* differentially affect breast stem cell fates, as highlighted by the effect of their inactivation on mouse mammary gland development. Indeed, whereas *SCRIB* knockdown affects ductal luminal epithelium through altered polarity processes, notably stem cell asymmetric cell division, giving rise to a hyperbranched ductal tree ([@bib9]), loss of Lano expression induces a delay in the development of the ductal epithelial tree, associated with hypobranching and reduced numbers of TEBs, which may be due to an overproduction of MaSCs. Another difference between the two paralogs lies in their different roles in cancer cell migration, as Lano downregulation increases velocity, in contrast to SCRIB loss ([@bib4], [@bib17]). As the role of SCRIB in stem cell fate and self-renewal goes beyond the mammary epithelium ([@bib19]), it will be interesting to study how Lano acts in other tissues, especially in the liver where its expression has been associated with hepatocellular carcinomas ([@bib10]). Although *SCRIB* and *LANO* are phylogenetically and structurally related ([@bib23]), our results suggest that they have functionally diverged. Our work stresses the importance of defining how Lano impacts on WNT secretion in the extracellular medium. WNT transcriptional levels do not appear to be affected by Lano, which rather seems to be involved in WNT3a stabilization, maturation, or the repression of WNT ligand secretion, potentially through vesicular or exosomal pathways ([@bib18]). Few Lano partners have been characterized. Among them we found Erbin ([@bib22]), another LAP family member which has recently been involved in vesicular trafficking ([@bib12]), and which might thus affect WNT secretion. Moreover, it will be worth assessing whether *Lano* expression could be used as a theranostic marker able to guide the administration of WNT signaling inhibitors. Thus, in breast tumors with low *Lano* expression, compounds targeting WNT signaling such as Porcupine inhibitors might be proposed as a therapeutic option, or drugs inhibiting WNT receptors (Frizzled) such as vantictumab, currently in phase I clinical trial ([@bib7]) for metastatic triple-negative breast cancers.

Experimental Procedures {#sec4}
=======================

Gene Expression Data Analysis and Breast Cancer Samples {#sec4.1}
-------------------------------------------------------

Data analysis of annotated clinical samples collected from 36 public datasets were performed using standard methods and are detailed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Statistical Analyses {#sec4.2}
--------------------

Statistical analyses were performed using GraphPad Prism v5.03 (GraphPad Software), multiple variance analysis (ANOVA). The number of experiments and significant range are indicated in each legend.

ELISAs, Immunofluorescence, and Immunoblot Analysis {#sec4.3}
---------------------------------------------------

ELISAs, immunofluorescence, and immunoblot analysis were carried out according to [@bib17] and are detailed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Cell Culture {#sec4.4}
------------

Cell culture was done according to [@bib5] and is detailed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

TCF/LEF Luciferase Report Assays {#sec4.5}
--------------------------------

TCF/LEF luciferase report assays were carried out according to [@bib5] and are detailed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

TEAD Assays {#sec4.6}
-----------

TEAD assays were performed using the 8xGTIIC promoter-luciferase reporter (\#34615, Addgene).

Animal Models {#sec4.7}
-------------

All experiments were performed using standard methods, detailed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}, in agreement with the French Guidelines for animal handling and approved by the local ethics committee APAFIS\#10719-2017071709337799 v2.
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